Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system

Biomaterials

Volumn 68, Issue , 2015, Pages 9-20

  Shrestha, Neha ^a   Shahbazi, Mohammad Ali ^a   Araújo, Francisca ^a,b,c   Mäkilä, Ermei ^a,d   Raula, Janne ^e   Kauppinen, Esko I ^e   Salonen, Jarno ^d   Sarmento, Bruno ^b,f   Hirvonen, Jouni ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF TURKU   (Finland)

^e AALTO UNIVERSITY   (Finland)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Aerosol flow reactor technology; Dipeptidyl peptidase 4; Glucagon like peptide 1; Oral protein drug delivery; Porous silicon nanoparticles

Indexed keywords

AEROSOLS; ATMOSPHERIC MOVEMENTS; CHITOSAN; ENZYME INHIBITION; NANOPARTICLES; NANOSYSTEMS; NONINVASIVE MEDICAL PROCEDURES; PEPTIDES; POROUS SILICON; SILICON COMPOUNDS; TARGETED DRUG DELIVERY;

AEROSOL FLOW REACTORS; DIPEPTIDYL PEPTIDASE; GLUCAGON-LIKE PEPTIDE-1; ORAL PROTEIN DRUG DELIVERIES; SILICON NANOPARTICLES;

CONTROLLED DRUG DELIVERY;

CHITOSAN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; IMIDE; N HYDROXYSUCCINIMIDE; NANOCARRIER; AEROSOL; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; DPP4 PROTEIN, HUMAN; DRUG COMBINATION; NANOCAPSULE; SILICON;

AEROSOL; AEROSOL FLOW REACTOR; ARTICLE; CELL INTERACTION; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; NANOFABRICATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; SURFACE AREA; SURFACE CHARGE; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; CACO 2 CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG COMBINATION; DRUG FORMULATION; INTESTINE ABSORPTION; INTESTINE MUCOSA; MICROFLUIDICS; ORAL DRUG ADMINISTRATION; PROCEDURES; SYNTHESIS; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; AEROSOLS; CACO-2 CELLS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DIPEPTIDYL PEPTIDASE 4; DRUG COMBINATIONS; DRUG COMPOUNDING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MICROFLUIDICS; NANOCAPSULES; PARTICLE SIZE; SILICON;

EID: 84939628067     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.045     Document Type: Article

References (52)

1. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8:147-166.
2. Park K., Kwon I.C., Park K. Oral protein delivery: current status and future prospect. React. Funct. Polym. 2011, 71:280-287.
3. Plapied L., Duhem N., des Rieux A., Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interf. Sci. 2011, 16:228-237.
4. Fonte P., Araújo F., Reis S., Sarmento B. Oral insulin delivery: how far are we?. J. Diab. Sci. Technol. 2013, 7:520-531.
5. Shahbazi M.A., Santos H.A. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr. Drug Metab. 2013, 14:28-56.
6. Araújo F., Shrestha N., Shahbazi M.A., Fonte P., Mäkilä E.M., Salonen J.J., Hirvonen J.T., Granja P.L., Santos H.A., Sarmento B. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 2014, 35:9199-9207.
7. Santos H.A., Mäkilä E.M., Airaksinen A.J., Bimbo L.M., Hirvonen J. Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. Nanomedicine (Lond) 2014, 9:535-554.
8. Santos H.A., Bimbo L.M., Lehto V.P., Airaksinen A.J., Salonen J., Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr. Drug Discov. Technol. 2011, 8:228-249.
9. Liu D., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P., Salonen J., Hirvonen J., Santos H.A. Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv. Funct. Mater 2013, 23:1893-1902.
10. Salonen J., Kaukonen A.M., Hirvonen J., Lehto V.-P. Mesoporous silicon in drug delivery applications. J. Pharm. Sci. 2008, 97:632-653.
11. Shrestha N., Shahbazi M.A., Araújo F., Zhang H., Mäkilä E.M., Kauppila J., Sarmento B., Salonen J.J., Hirvonen J.T., Santos H.A. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 2014, 35:7172-7179.
12. Shahbazi M.-A., Herranz B., Santos H.A. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter 2012, 2:296-312.
13. Kovalainen M., Mönkäre J., Mäkilä E.M., Salonen J., Lehto V.P., Herzig K.H., Järvinen K. Mesoporous silicon (psi) for sustained peptide delivery: effect of PSi microparticle surface chemistry on peptide YY3-36 release. Pharm. Res. 2012, 29:837-846.
14. Liu D., Bimbo L.M., Mäkilä E.M., Villanova F., Kaasalainen M., Herranz-Blanco B., Caramella C.M., Lehto V.P., Salonen J., Herzig K.H., Hirvonen J., Santos H.A. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J. Control. Release 2013, 170:268-278.
15. Sonaje K., Lin K.J., Tseng M.T., Wey S.P., Su F.Y., Chuang E.Y., Hsu C.W., Chen C.T., Sung H.W. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011, 32:8712-8721.
16. Liu D., Zhang H., Mäkilä E.M., Fan J., Herranz-Blanco B., Wang C.F., Rosa R., Ribeiro A.J., Salonen J., Hirvonen J., Santos H.A. Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran nanocomposites for precisely controlled combination chemotherapy. Biomaterials 2015, 39:249-259.
17. Nykänen A., Rahikkala A., Hirvonen S.P., Aseyev V., Tenhu H., Mezzenga R., Raula J., Kauppinen E., Ruokolainen J. Thermally sensitive block copolymer particles prepared via aerosol flow reactor method: morphological characterization and behavior in water. Macromolecules 2012, 45:8401-8411.
18. Rahikkala A., Junnila S., Vartiainen V., Ruokolainen J., Ikkala O., Kauppinen E., Raula J. Polypeptide-based aerosol nanoparticles: self-assembly and control of conformation by solvent and thermal annealing. Biomacromolecules 2014, 15:2607-2615.
19. Raula J., Eerikäinen H., Kauppinen E.I. Influence of the solvent composition on the aerosol synthesis of pharmaceutical polymer nanoparticles. Int. J. Pharm. 2004, 284:13-21.
20. Eerikäinen H., Kauppinen E.I. Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int. J. Pharm. 2003, 263:69-83.
21. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3434-3438.
22. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr. Diab. Rep. 2003, 3:365-372.
23. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003, 144:5145-5148.
24. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003, 17:161-171.
25. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80:952-957.
26. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
27. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
28. Ahrén B. DPP-4 inhibitors. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:517-533.
29. Eerikäinen H., Watanabe W., Kauppinen E.I., Ahonen P.P. Aerosol flow reactor method for synthesis of drug nanoparticles. Eur. J. Pharm. Biopharm. 2003, 55:357-360.
30. Hillamo R.E., Kauppinen E.I. On the performance of the Berner low pressure impactor. Aerosol. Sci. Technol. 1991, 14:33-47.
31. Antunes F., Andrade F., Araújo F., Ferreira D., Sarmento B. Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur. J. Pharm. Biopharm. 2013, 83:427-435.
32. Shahbazi M.-A., Shrestha N., Mäkilä E., Araújo F., Correia A., Ramos T., Sarmento B., Salonen J., Hirvonen J., Santos H. A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors. Nano Res. 2015, 8:1505-1521.
33. Hamuro Y., Coales S.J., Molnar K.S., Tuske S.J., Morrow J.A. Specificity of immobilized porcine pepsin in H/D exchange compatible conditions. Rapid Commun. Mass Spectrom. 2008, 22:1041-1046.
34. Johnston N., Dettmar P.W., Bishwokarma B., Lively M.O., Koufman J.A. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope 2007, 117:1036-1039.
35. Bellmann S., Carlander D., Fasano A., Momcilovic D., Scimeca J.A., Waldman W.J., Gombau L., Tsytsikova L., Canady R., Pereira D.I.A., Lefebvre D.E. Mammalian gastrointestinal tract parameters modulating the integrity, surface properties, and absorption of food-relevant nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7:609-622.
36. Kojima H., Yoshihara K., Sawada T., Kondo H., Sako K. Extended release of a large amount of highly water-soluble diltiazem hydrochloride by utilizing counter polymer in polyethylene oxides (PEO)/polyethylene glycol (PEG) matrix tablets. Eur. J. Pharm. Biopharm. 2008, 70:556-562.
37. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 2010, 75:1-18.
38. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 2002, 6:319-327.
39. Villhauer E.B., Brinkman J.A., Naderi G.B., Dunning B.E., Mangold B.L., Mone M.D., Russell M.E., Weldon S.C., Hughes T.E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2002, 45:2362-2365.
40. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., Villhauer E.B. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999, 38:11597-11603.
41. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul. Toxicol. Pharmacol. 2010, 56:290-299.
42. Arai K., Kinumaki Toyosuke, Fujita Takao Toxicity of Chitosan. Bull. Tokai Reg. Fish. Res. Lab. 1968, 56:89-94.
43. Kean T., Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62:3-11.
44. Garcia-Fuentes M., Alonso M.J. Chitosan-based drug nanocarriers: where do we stand?. J. Control. Release 2012, 161:496-504.
45. Schimpel C., Teubl B., Absenger M., Meindl C., Frohlich E., Leitinger G., Zimmer A., Roblegg E. Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles. Mol. Pharmaceutics 2014, 11:808-818.
46. Lai Y.H., D'Souza M.J. Microparticle transport in the human intestinal M cell model. J. Drug Target. 2008, 16:36-42.
47. Hilgendorf C., Spahn-Langguth H., Regardh C.G., Lipka E., Amidon G.L., Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J. Pharm. Sci. 2000, 89:63-75.
48. Sarmento B., Andrade F., da Silva S.B., Rodrigues F., das Neves J., Ferreira D. Cell-based in vitro models for predicting drug permeability. Expert Opin. Drug Metab. Toxicol. 2012, 8:607-621.
49. Bakhru S.H., Furtado S., Morello A.P., Mathiowitz E. Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev. 2013, 65:811-821.
50. Fernandes M., Goncalves I.C., Nardecchia S., Amaral I.F., Barbosa M.A., Martins M.C.L. Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. Int. J. Pharm. 2013, 454:116-124.
51. Sonaje K., Chuang E.Y., Lin K.J., Yen T.C., Su F.Y., Tseng M.T., Sung H.W. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol. Pharmaceutics 2012, 9:1271-1279.
52. des Rieux A., Ragnarsson E.G., Gullberg E., Preat V., Schneider Y.J., Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 2005, 25:455-465.